Ann: Pfizer raises scheme consideration to A$0.208 per share, page-29

Yeah that would have been nice at 4c...
Conviction plays are great, but, don't always work out. Like I said I'm surprised Pfizer are interested based on the results of clinical trials, I'm sure many would have sold at a loss, but good on those that had the conviction to hold as it didn't look rosey at the lows Pfizer threw RAP a lifeline. You can't say you never doubted your conviction, would have felt well and truly shagged down >50%, and, you were wrong to end up with an average of 13.5c should be sitting on multi bags if you played it correctly. Was always the chance players such as Pfizer saw no value here, a phone cough test with mediocre accuracy had no guarantees. So, off your high horse pal, nothing but blind faith and luck.